Switzerland’s privately funded biotech sector reported record capital generation and hiring activity in 2025, according to an industry report. Private biotechs raised CHF 1.15 billion (US$1.47 billion) in 2025, up 38% versus 2024, with the sector accounting for 45% of all capital raised in the Swiss life-sciences space. The figures signal sustained investor appetite for early- and growth-stage companies in a market that has grappled with shifting risk appetite and cross-border financing dynamics. The report also points to employment growth alongside investment, suggesting scaling rather than purely speculative funding.